Efficacy and safety of cerivastatin in primary hypercholesterolemia: A long term comparative titration study with simvastatin

Canadian Journal of Cardiology

Volumn 15, Issue 5, 1999, Pages 545-555

  Leiter, L A ^a   Hanna, K ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b NONE

Author keywords

Cholesterol; Hypercholesterolemia

Indexed keywords

APOLIPOPROTEIN B; CERIVASTATIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; ASTHENIA; BACKACHE; CANADA; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLATULENCE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; INFLUENZA; LIPOPROTEIN BLOOD LEVEL; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; ORAL DRUG ADMINISTRATION; PARALLEL DESIGN; PHARYNGITIS; RANDOMIZED CONTROLLED TRIAL; THORAX PAIN; TITRIMETRY;

EID: 0033060079     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Kannel WB, Castelli WP, Gordon T, et al. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham Study. Ann Intern Med 1971;74:1-12.
2. Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial: risk factor changes and mortality results. JAMA 1982;248:1465-77.
3. The Lipid Research Clinics Program. The lipid research clinics Coronary Primary Prevention Trial results I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-64.
4. Frick HM, Elo O, Haapa K, et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45.
5. LaRosa JS. At what levels of total low or high-density lipoprotein cholesterol should diet/drug therapy be initiated? United States Guidelines. Am J Cardiol 1990;65:7F-10F.
6. Steinberg D, Witztum JL. Lipoproteins and atherogenesis. Current concepts. JAMA 1990;264:3047-52.
7. Kane JP, Malloy MJ, Ports TA, et al. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990;264:3007-12.
8. Brown BG, Zhao X-Q, Sacco DE, et al. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993;87:1781-91.
9. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994;308:367-73.
10. Furberg CD, Pitt B, Byington RP, et al. For the PLAC-I and PLAC-II investigators. Reduction in coronary events during treatment with pravastatin. Am J Cardiol 1995;76:60C-3C.
11. Furberg CD, Adams HP, Appelgate WB, et al for the Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation 1994;90:1679-87.
12. The MAAS Investigators. Effect of simvastatin on coronary atheroma: the multicentre anti-atheroma study (MAAS). Lancet 1994;344:633-8.
13. Salonen R, Nyyssonen K, Prokkala-Sarataho E, el al. The Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins and atherosclerotic progression. Am J Cardiol 1995;76:34C-9C.
14. Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. Circulation 1994;89:959-68.
15. Shepherd J, Cobbe SM, Ford I, et al. The West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
16. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
17. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
18. Illingworth DR, Bacon SP, Larsen KK. Long-term experience with HMG-CoA reductase inhibitors in the therapy of hypercholesterolaemia. Atheroscler Rev 1988;18:161-87.
19. Blum CB, Levy RI. Current therapy for hypercholesterolaemia. JAMA 1989;261:3582-7.
20. Hebert PR, Gaziano JM, Chan KS, et al. Cholesterol lowering with statin drugs, risk of stroke and total mortality. JAMA 1997;278:313-21.
21. Angerbauer R, Bischoff H, Steinke W, Ritter W. Bay w 6228. Rivastatin. Drugs Future 1994;19:537-41.
22. Stein E, Sprecher D, Allenby KS, et al. Cerivastatin, a new potent synthetic HMG-CoA reductase inhibitor: effect of 0.2 mg daily in subjects with primary hypercholesterolaemia. J Cardiovasc Pharmacol Ther 1997;2:7-16.
23. Bischoff H, Angerbauer R, Bender J, et al. Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor. Atherosclerosis 1997;135:119-30. (Abst)
24. Steinke W, Yamashita S, Tabei M, et al. Cerivastatin, a new inhibitor of HMG-CoA reductase: pharmacokinetics in rats and dogs. Jpn Pharmacol Ther 1996;24:7-27.
25. Mazzu A, Lettieri J, Hogan C, et al. A multiple-dose study on the safety and pharmacokinetics of Cerivastatin in young and elderly male volunteers. Atherosclerosis 1997;130(Suppl):S29. (Abst)
26. Vormfelde SV, Gleiter CH, Freudenthaler S, et al. Pharmacokinetics of single dose cerivastatin in subjects with normal and impaired renal function. Atherosclerosis 1997;130:S33. (Abst)
27. Frey R, Mazzu A, Ritter W, et al. Safety and tolerability of rivastatin, a novel HMG-CoA reductase inhibitor, in phase-1 single dose studies. Naunyn Schmiedebergs Arch Pharmacol 1993;33(Suppl):119. (Abst)
28. Stein E, Isaacsohn J, Stoltz R, et al. Efficacy and safety of 0.8 mg dosage of cerivastatin, a novel HMF-CoA reductase inhibitor. J Am Coll Cardiol 1998;31(Suppl A):281A. (Abst)
29. Steiner PM, Freidel J, Bremner WF, Stein EA. Standardization of micromethods for plasma cholesterol, triglycerides and HDL-cholesterol with the Lipid Clinics methodology. J Clin Chem 1981;19:850.
30. Lipids Research Clinics Program. Manual of Laboratory Operations: Lipid and Lipoprotein Analysis. Washington: US Department of Health, Education and Welfare, 1982;75:628.
31. Warnick GR, Albers JJ. A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol. J Lipid Res 1978;19:65-76.
32. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
33. Albers JJ, Marcovina SM, Kennedy H. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. II. Evaluation and selection of candidate reference materials. Clin Chem 1992;38:658-62.
34. Stein EA, Kumbla L, Miller J, Stivastiva L, Kashyap M. Development and evaluation of a competitive ELISA for Lp(a). Clin Chem 1992;38:1067. (Abst 0566)
35. Frohlich J, Brun LD, Blank D, et al. Comparison of the short term efficacy and tolerability of lovastatin and simvastatin in the management of primary hypercholesterolemia. Can J Cardiol 1993;9;405-12.
36. Schall R, Müller O, Hondt HKL, et al. No pharmacokinetic or pharmacodynamic interaction between rivastatin and warfarin. J Clin Pharmacol 1995;36:306-13.
37. Blum CB. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-co-enzyme A reductase. Am J Cardiol 1994;73:3D-11D.
38. Lettieri J, Krol G, Mazzu A, et al. Lack of pharmacokinetic interaction between cerivastatin, a new HMG-CoA reductase inhibitor and digoxin. Atherosclerosis 1997;130:S29. (Abst)